Freedom Study: Myfortic in Kidney Transplant Patients

Novartis

Status and phase

Completed

Phase 3

Conditions

Kidney Transplantation

Treatments

Drug: Myfortic

Study type

Interventional

Funder types

Industry

Identifiers

NCT00101738

CERL080A2404

Details and patient eligibility

About

The primary objective of the study is to evaluate that 3 immunosuppressant regimens will have comparable kidney function results in kidney transplant patients.

Enrollment

342 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Males and females aged 18 to 75 years.
Recipients of first, heart-beating cadaveric, living unrelated or living related non-HLA identical donor kidney transplant, treated with Simulect® and Neoral® as primary immunosuppression.

Exclusion criteria

Second or subsequent kidney transplant or multi-organ recipients (e.g. kidney and pancreas) or previous transplant with any other organ.
Kidneys from non-heart beating donors or HLA identical living related donors.
ABO incompatibility against the donor.